[ad_1]
Christian televangelist Pat Robertson, who helped make religion central to Republican Party politics in America through his Christian Coalition, has died at 93. What do you think?
“We’ll never know which minority group he’d blame for his death.”
Tommy Crimmins, Cocking Assistant
“Must be God’s punishment for some gay stuff he did.”
Derrick Brock, Unemployed
“Which TV channel can cure my diabetes now?”
Carla Laskowski, Tipping Consultant
[ad_2]
[ad_1]
Ozempic users don’t want to think of themselves as taking a harmful drug.
This is actually incredibly heartwarming.
Sure, why don’t they go ahead and do something that hasn’t ever been achieved by any human in history?
Aren’t we at a point where every commercial is supposed to do that?
You just shouldn’t say this to anyone.
You could’ve gone with a smaller brass instrument to be kind.
You fool, you just made them gain all the weight back with that one question.
What? It would be rude not to offer!
They may become more of an asshole after they lose the weight.
Ozempic for aging hasn’t finished clinical trials.
Don’t give them any ideas.
Don’t force an Ozempic user or anyone else to feed into your totally baseless belief in your attractiveness, you hideous slug.
Struggling with obesity is already tough enough without being reminded of how sexually loose their brother is.
Gate-keeping other people’s medication? Not a good look.
There are better ways to let someone you care about know you’re concerned for their health and well-being.
Although it’s definitely more ideal to be nothing more than a floating, weightless orb of light, some people can’t avoid having a body of flesh to inhabit.
If you really loved them, you would follow them on this weight-loss journey, no matter your own preferences.
[ad_2]
[ad_1]
Advisor Group Holdings Inc. increased its position in shares of Medtronic plc (NYSE:MDT – Get Rating) by 11.5% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 609,610 shares of the medical technology company’s stock after buying an additional 62,922 shares during the period. Advisor Group Holdings Inc.’s holdings in Medtronic were worth $47,407,000 at the end of the most recent quarter.
Several other institutional investors and hedge funds have also recently made changes to their positions in MDT. Vanguard Group Inc. lifted its stake in shares of Medtronic by 0.9% during the 3rd quarter. Vanguard Group Inc. now owns 123,861,994 shares of the medical technology company’s stock worth $10,001,857,000 after purchasing an additional 1,056,995 shares during the last quarter. BlackRock Inc. lifted its position in shares of Medtronic by 5.1% during the third quarter. BlackRock Inc. now owns 115,998,561 shares of the medical technology company’s stock valued at $9,366,883,000 after buying an additional 5,620,477 shares during the last quarter. State Street Corp boosted its holdings in shares of Medtronic by 1.6% in the 3rd quarter. State Street Corp now owns 58,989,713 shares of the medical technology company’s stock valued at $4,802,998,000 after buying an additional 928,929 shares in the last quarter. Bank of New York Mellon Corp grew its position in shares of Medtronic by 33.1% in the 3rd quarter. Bank of New York Mellon Corp now owns 19,374,686 shares of the medical technology company’s stock worth $1,564,508,000 after buying an additional 4,816,172 shares during the last quarter. Finally, Royal Bank of Canada raised its stake in shares of Medtronic by 4.6% during the 3rd quarter. Royal Bank of Canada now owns 13,702,223 shares of the medical technology company’s stock worth $1,106,453,000 after acquiring an additional 608,587 shares in the last quarter. 80.37% of the stock is currently owned by institutional investors.
MDT has been the topic of several analyst reports. Deutsche Bank Aktiengesellschaft lifted their price target on shares of Medtronic from $80.00 to $87.00 in a report on Wednesday, February 22nd. Royal Bank of Canada reissued a “sector perform” rating and issued a $89.00 price target on shares of Medtronic in a report on Friday, April 21st. Wells Fargo & Company upgraded shares of Medtronic from an “equal weight” rating to an “overweight” rating and upped their price objective for the company from $77.00 to $100.00 in a report on Monday, April 24th. Truist Financial lifted their target price on shares of Medtronic from $88.00 to $93.00 in a research note on Monday, April 24th. Finally, Mizuho cut their price target on shares of Medtronic from $100.00 to $95.00 and set a “buy” rating on the stock in a research note on Tuesday, January 24th. Two equities research analysts have rated the stock with a sell rating, eleven have assigned a hold rating and five have given a buy rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Hold” and an average price target of $90.11.
MDT opened at $89.50 on Tuesday. The firm has a fifty day moving average price of $84.32 and a 200 day moving average price of $82.04. Medtronic plc has a 1 year low of $75.76 and a 1 year high of $106.06. The stock has a market cap of $119.07 billion, a P/E ratio of 29.44, a P/E/G ratio of 2.15 and a beta of 0.71. The company has a debt-to-equity ratio of 0.43, a current ratio of 1.76 and a quick ratio of 1.39.
Medtronic (NYSE:MDT – Get Rating) last posted its earnings results on Tuesday, February 21st. The medical technology company reported $1.30 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.27 by $0.03. The business had revenue of $7.70 billion for the quarter, compared to analyst estimates of $7.53 billion. Medtronic had a net margin of 13.20% and a return on equity of 13.37%. The company’s revenue for the quarter was down .8% on a year-over-year basis. During the same period in the prior year, the company posted $1.37 EPS. Equities research analysts anticipate that Medtronic plc will post 5.28 earnings per share for the current year.
The firm also recently disclosed a quarterly dividend, which was paid on Friday, April 14th. Stockholders of record on Friday, March 24th were given a $0.68 dividend. This represents a $2.72 dividend on an annualized basis and a dividend yield of 3.04%. The ex-dividend date of this dividend was Thursday, March 23rd. Medtronic’s dividend payout ratio (DPR) is presently 89.47%.
Medtronic Plc is a medical technology company, which engages in the development, manufacture, distribution, and sale of device-based medical therapies and services. It operates through the following segments: Cardiovascular Porrtfolio, Neuroscience Portfolio, Medical Surgical Portfolio, and Diabetes Operating Unit.
Receive News & Ratings for Medtronic Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Medtronic and related companies with MarketBeat.com’s FREE daily email newsletter.
[ad_2]
ABMN Staff
Source link
[ad_1]
In a groundbreaking move, Minnesota has joined the ranks of states embracing the legalization of recreational marijuana. Senators in the state passed a bill over the weekend, making Minnesota the 23rd state to allow adults over the age of 21 to partake in the use of cannabis for recreational purposes. The measure has already received approval from the House and is now on its way to Democratic Gov. Tim Walz, who has enthusiastically pledged to sign it into law.
Supporters of the bill argue that its implementation will not only enhance public health and safety but also promote social justice. However, opponents hold a different perspective, asserting that the legislation will have adverse effects on health and safety.
Under the proposed measure, effective from August 1, individuals will be legally allowed to possess, use, and even grow marijuana in the comfort of their homes. However, it may take at least a year for retail sales to commence at dispensaries.
To regulate the industry and generate revenue, the bill includes a 10% tax on cannabis products in addition to existing…
[ad_2]
MMP News Author
Source link
[ad_1]
Shares of Aurora Cannabis Inc. (NYSE:ACB – Get Rating) have earned a consensus recommendation of “Hold” from the seven analysts that are covering the company, Marketbeat.com reports. Three equities research analysts have rated the stock with a hold recommendation and one has issued a buy recommendation on the company. The average 12-month price objective among brokerages that have issued a report on the stock in the last year is $1.40.
ACB has been the topic of a number of research analyst reports. CIBC decreased their price objective on shares of Aurora Cannabis from C$2.25 to C$1.75 in a report on Monday, February 13th. Stifel Nicolaus dropped their target price on shares of Aurora Cannabis from C$1.75 to C$1.45 in a report on Friday, January 27th.
A number of institutional investors have recently made changes to their positions in ACB. Commonwealth Equity Services LLC boosted its position in Aurora Cannabis by 18.8% during the 4th quarter. Commonwealth Equity Services LLC now owns 177,313 shares of the company’s stock worth $163,000 after acquiring an additional 28,074 shares during the last quarter. Swiss National Bank lifted its holdings in Aurora Cannabis by 6.5% during the 4th quarter. Swiss National Bank now owns 728,972 shares of the company’s stock valued at $673,000 after purchasing an additional 44,300 shares during the last quarter. K2 Principal Fund L.P. acquired a new stake in Aurora Cannabis during the 4th quarter valued at $506,000. TD Asset Management Inc lifted its holdings in shares of Aurora Cannabis by 34.6% during the fourth quarter. TD Asset Management Inc now owns 241,318 shares of the company’s stock worth $223,000 after buying an additional 62,036 shares in the last quarter. Finally, Foundations Investment Advisors LLC increased its position in shares of Aurora Cannabis by 66.6% in the fourth quarter. Foundations Investment Advisors LLC now owns 125,003 shares of the company’s stock worth $115,000 after purchasing an additional 49,985 shares during the period. 13.97% of the stock is owned by institutional investors.
ACB stock opened at $0.56 on Monday. The firm has a 50-day moving average of $0.67 and a two-hundred day moving average of $0.94. Aurora Cannabis has a 12 month low of $0.55 and a 12 month high of $3.15. The company has a current ratio of 4.08, a quick ratio of 3.16 and a debt-to-equity ratio of 0.33. The company has a market cap of $196.91 million, a price-to-earnings ratio of -0.09 and a beta of 2.57.
Aurora Cannabis (NYSE:ACB – Get Rating) last issued its quarterly earnings results on Thursday, February 9th. The company reported ($0.14) EPS for the quarter, missing the consensus estimate of ($0.07) by ($0.07). Aurora Cannabis had a negative net margin of 817.07% and a negative return on equity of 62.73%. The business had revenue of $50.95 million during the quarter, compared to analysts’ expectations of $42.60 million. As a group, analysts forecast that Aurora Cannabis will post -0.35 earnings per share for the current fiscal year.
Aurora Cannabis, Inc engages in the production, distribution, and sale of cannabis products. It also produces and sells indoor cultivation systems and hemp related food products. The firm operates through the Canadian Cannabis and International Cannabis segments. Aurora Cannabis was founded by Terry Booth and Steve Dobler on December 21, 2006 and is headquartered in Edmonton, Canada.
Receive News & Ratings for Aurora Cannabis Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Aurora Cannabis and related companies with MarketBeat.com’s FREE daily email newsletter.
[ad_2]
ABMN Staff
Source link
[ad_1]
Disclosure: Our goal is to feature products and services that we think you’ll find interesting and useful. If you purchase them, Entrepreneur may get a small share of the revenue from the sale from our commerce partners.
As the 70M+ baby-boomer population ages, a huge opportunity for medical companies to help repair and preserve their bodies is arising. Enter Monogram Orthopedics, a company reimagining the knee replacement surgery process with robotic surgical assistants and patient-specific implants.
With demand rising for more and better knee replacement surgery, the industry is projected to reach $26 billion by 2027, and Monogram is one of the few rising to meet it. Not only have they developed a new way to conduct joint surgery, but they’ve taken a novel approach to the joints themselves.
Here’s what makes Monogram such an interesting startup and why investors should consider this opportunity.
For about 40 years, joint replacement innovation has been stuck in a holding pattern. Market leaders have kept using the same hacksaws, jigs, and bone cement – not to mention carrying out the same imprecise surgeries with extended recovery times.
But they’re not keeping the status quo “because it works.” As it turns out, 36% of people end up wishing they never went through with the joint surgery. The market has simply not been able to supply them with anything better than generic replacements that wear over time and lead to potentially more joint problems due to a poor fit.
That’s the problem Monogram came to solve with ultra-precise robotic joint surgery and custom 3D-printed joints. Better tools and knee replacements have the potential to give each patient their own personalized fit to prevent wobble and last longer.
The Monogram team and its robots have already performed successful demos in front of thousands of online viewers in Monogram’s own state-of-the-art cadaver lab. And the company is working to grab a sizable portion of this market moving forward.
To put things into perspective, there are 933,000 knee replacements each year, and 100,000 of them fail. This is in part because 92% of them use cement with generic implants that are not optimized to each patient. Not to mention, the risk of human error.
One of the reasons for this is that only four major competitors control 82% of the joint replacement market: Stryker, Zimmer, Smith & Nephew, and DepuySynthes. They will have to adapt at some point, as up to 50% of all joint replacements are predicted to be robotic by 2030. But with 20 patent filings and an aggressive development push, the company believes it may have a considerable first-mover advantage.
Here’s what’s next for Monogram and how you can get involved.
The company is intending to expand its reach with a direct NASDAQ listing.
They’re kicking it off with a Reg A investment opportunity where shares will sell at a fixed price of $7.25 a share before the intended listing, after which they will trade freely on the market.
This basically means that Entrepreneur readers have an opportunity to invest in the company at a fixed price while before the intended public listing. This kind of investing used to be restricted to big banks and venture capitalists, but crowdfunding enables retail investors to get in on companies like Monogram before they list on a public exchange.
Learn more about becoming a Monogram shareholder before they’re publicly-traded.
Disclosure: This is a paid advertisement for Monogram Orthopedics’ Regulation A+ offering. Learn more at invest.monogramorthopedics.com/disclaimers
Entrepreneur may receive monetary compensation by the issuer, or its agency, for publicizing the offering of the issuer’s securities. Entrepreneur and the issuer of this offering make no promises, representations, warranties, or guarantees that any of the services will result in a profit or will not result in a loss.
[ad_2]
StackCommerce
Source link
[ad_1]
Nations Financial Group Inc. IA ADV lifted its holdings in shares of Gilead Sciences, Inc. (NASDAQ:GILD – Get Rating) by 60.2% during the 4th quarter, according to the company in its most recent filing with the SEC. The fund owned 5,501 shares of the biopharmaceutical company’s stock after purchasing an additional 2,068 shares during the period. Nations Financial Group Inc. IA ADV’s holdings in Gilead Sciences were worth $472,000 as of its most recent filing with the SEC.
Other institutional investors and hedge funds also recently made changes to their positions in the company. Legacy Bridge LLC bought a new position in shares of Gilead Sciences during the 4th quarter valued at $30,000. Concord Wealth Partners bought a new stake in Gilead Sciences in the 4th quarter worth $33,000. Hanseatic Management Services Inc. bought a new stake in Gilead Sciences in the 4th quarter worth $37,000. EWG Elevate Inc. bought a new stake in Gilead Sciences in the 4th quarter worth $45,000. Finally, Duncker Streett & Co. Inc. grew its holdings in Gilead Sciences by 266.7% in the 4th quarter. Duncker Streett & Co. Inc. now owns 550 shares of the biopharmaceutical company’s stock worth $47,000 after acquiring an additional 400 shares during the last quarter. Institutional investors own 78.72% of the company’s stock.
In other Gilead Sciences news, insider Merdad Parsey sold 6,126 shares of the company’s stock in a transaction that occurred on Monday, March 13th. The shares were sold at an average price of $78.99, for a total value of $483,892.74. Following the completion of the transaction, the insider now directly owns 70,130 shares in the company, valued at $5,539,568.70. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Company insiders own 0.16% of the company’s stock.
Shares of GILD stock opened at $78.52 on Friday. The company has a 50 day moving average price of $81.47 and a 200-day moving average price of $82.60. Gilead Sciences, Inc. has a 52 week low of $57.17 and a 52 week high of $89.74. The firm has a market capitalization of $98.06 billion, a PE ratio of 17.72, a P/E/G ratio of 0.91 and a beta of 0.38. The company has a quick ratio of 1.08, a current ratio of 1.37 and a debt-to-equity ratio of 1.14.
Gilead Sciences (NASDAQ:GILD – Get Rating) last announced its earnings results on Thursday, April 27th. The biopharmaceutical company reported $1.37 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.63 by ($0.26). The business had revenue of $6.35 billion for the quarter, compared to the consensus estimate of $6.33 billion. Gilead Sciences had a net margin of 20.65% and a return on equity of 39.35%. The business’s quarterly revenue was down 3.6% compared to the same quarter last year. During the same quarter last year, the firm posted $2.12 earnings per share. As a group, equities research analysts expect that Gilead Sciences, Inc. will post 6.75 earnings per share for the current year.
The company also recently declared a quarterly dividend, which will be paid on Thursday, June 29th. Shareholders of record on Thursday, June 15th will be given a $0.75 dividend. The ex-dividend date of this dividend is Wednesday, June 14th. This represents a $3.00 dividend on an annualized basis and a dividend yield of 3.82%. Gilead Sciences’s payout ratio is currently 67.72%.
A number of equities research analysts have issued reports on the stock. Mizuho raised their price target on shares of Gilead Sciences from $88.00 to $101.00 and gave the stock a “buy” rating in a report on Tuesday, February 14th. Barclays lifted their target price on shares of Gilead Sciences from $76.00 to $84.00 and gave the company an “equal weight” rating in a research note on Wednesday, January 18th. Morgan Stanley lifted their target price on shares of Gilead Sciences from $81.00 to $85.00 and gave the company an “equal weight” rating in a research note on Wednesday, April 12th. Piper Sandler lifted their target price on shares of Gilead Sciences from $111.00 to $112.00 and gave the company an “overweight” rating in a research note on Friday, February 3rd. Finally, StockNews.com initiated coverage on shares of Gilead Sciences in a research note on Thursday, March 16th. They set a “strong-buy” rating on the stock. Nine research analysts have rated the stock with a hold rating, eight have assigned a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, Gilead Sciences currently has a consensus rating of “Moderate Buy” and a consensus price target of $89.60.
Gilead Sciences, Inc is a biopharmaceutical company, which engages in the research, development, and commercialization of medicines in areas of unmet medical need. The firm’s primary areas of focus include human immunodeficiency virus, acquired immunodeficiency syndrome, liver diseases, hematology, oncology, and inflammation and respiratory diseases.
Want to see what other hedge funds are holding GILD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Gilead Sciences, Inc. (NASDAQ:GILD – Get Rating).
Receive News & Ratings for Gilead Sciences Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Gilead Sciences and related companies with MarketBeat.com’s FREE daily email newsletter.
[ad_2]
ABMN Staff
Source link
[ad_1]
Glass Jacobson Investment Advisors llc bought a new position in Medtronic plc (NYSE:MDT – Get Rating) in the 4th quarter, Holdings Channel.com reports. The fund bought 1,000 shares of the medical technology company’s stock, valued at approximately $78,000.
Several other hedge funds and other institutional investors also recently modified their holdings of the stock. Brinker Capital Investments LLC increased its position in shares of Medtronic by 6.7% in the 4th quarter. Brinker Capital Investments LLC now owns 40,243 shares of the medical technology company’s stock worth $3,128,000 after purchasing an additional 2,535 shares during the last quarter. Westpac Banking Corp increased its position in shares of Medtronic by 0.4% in the 4th quarter. Westpac Banking Corp now owns 114,823 shares of the medical technology company’s stock worth $8,924,000 after purchasing an additional 463 shares during the last quarter. Bogart Wealth LLC increased its position in shares of Medtronic by 20.3% in the 4th quarter. Bogart Wealth LLC now owns 46,998 shares of the medical technology company’s stock worth $3,653,000 after purchasing an additional 7,945 shares during the last quarter. Ropes Wealth Advisors LLC increased its position in shares of Medtronic by 14.3% in the 4th quarter. Ropes Wealth Advisors LLC now owns 3,981 shares of the medical technology company’s stock worth $309,000 after purchasing an additional 497 shares during the last quarter. Finally, Glassman Wealth Services increased its position in shares of Medtronic by 9.5% in the 4th quarter. Glassman Wealth Services now owns 2,705 shares of the medical technology company’s stock worth $210,000 after purchasing an additional 235 shares during the last quarter. Institutional investors own 80.37% of the company’s stock.
Shares of NYSE:MDT opened at $90.95 on Friday. The company has a 50 day moving average of $81.86 and a 200-day moving average of $81.47. The firm has a market cap of $121.00 billion, a P/E ratio of 29.92, a P/E/G ratio of 2.16 and a beta of 0.71. Medtronic plc has a twelve month low of $75.76 and a twelve month high of $106.63. The company has a current ratio of 1.76, a quick ratio of 1.39 and a debt-to-equity ratio of 0.43.
Medtronic (NYSE:MDT – Get Rating) last issued its quarterly earnings results on Tuesday, February 21st. The medical technology company reported $1.30 earnings per share for the quarter, topping analysts’ consensus estimates of $1.27 by $0.03. The company had revenue of $7.70 billion during the quarter, compared to analyst estimates of $7.53 billion. Medtronic had a net margin of 13.20% and a return on equity of 13.37%. The business’s revenue for the quarter was down .8% compared to the same quarter last year. During the same period in the prior year, the business posted $1.37 EPS. As a group, analysts anticipate that Medtronic plc will post 5.28 earnings per share for the current fiscal year.
The business also recently declared a quarterly dividend, which was paid on Friday, April 14th. Stockholders of record on Friday, March 24th were paid a $0.68 dividend. This represents a $2.72 dividend on an annualized basis and a dividend yield of 2.99%. The ex-dividend date of this dividend was Thursday, March 23rd. Medtronic’s dividend payout ratio is currently 89.47%.
Several research firms have recently commented on MDT. Deutsche Bank Aktiengesellschaft lifted their price target on shares of Medtronic from $80.00 to $87.00 in a report on Wednesday, February 22nd. Mizuho decreased their price target on shares of Medtronic from $100.00 to $95.00 and set a “buy” rating for the company in a report on Tuesday, January 24th. UBS Group lowered shares of Medtronic from a “buy” rating to a “sell” rating and decreased their price target for the company from $127.00 to $79.00 in a report on Wednesday, March 29th. StockNews.com began coverage on shares of Medtronic in a report on Thursday, March 16th. They issued a “buy” rating for the company. Finally, Wells Fargo & Company raised shares of Medtronic from an “equal weight” rating to an “overweight” rating and lifted their price target for the company from $77.00 to $100.00 in a report on Monday, April 24th. Two equities research analysts have rated the stock with a sell rating, eleven have assigned a hold rating and six have assigned a buy rating to the stock. Based on data from MarketBeat, the stock has an average rating of “Hold” and an average target price of $91.79.
Medtronic Plc is a medical technology company, which engages in the development, manufacture, distribution, and sale of device-based medical therapies and services. It operates through the following segments: Cardiovascular Porrtfolio, Neuroscience Portfolio, Medical Surgical Portfolio, and Diabetes Operating Unit.
Want to see what other hedge funds are holding MDT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Medtronic plc (NYSE:MDT – Get Rating).
Receive News & Ratings for Medtronic Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Medtronic and related companies with MarketBeat.com’s FREE daily email newsletter.
[ad_2]
ABMN Staff
Source link
[ad_1]
Dogs and cats come through our doors for various reasons, and many of them have something in common: they need life-saving medical attention. These pets may come to us from Austin Animal Center or from under-resourced shelters throughout Texas. Fortunately, APA!’s programs, such as our Medical Triage & Wellness Clinic, are able to provide the care needed to give these pets a chance at life.
Our skilled medical team cares for hundreds of pets each year with injuries more extensive than many shelters can care for including pets with severe orthopedic injuries.
Each case is approached with care and consideration for what will be the most beneficial and most comfortable solution to support animals throughout the remainder of their lives. Our veterinarians explore many paths to help the pet heal, and sometimes, in the case of orthopedic injuries, that may mean amputation of a limb. That’s what happened to Hercules, who arrived in our care with a badly wounded leg. The best medical attention from our team combined with the attentive care from his foster family could not save his leg. While Hercules’ skin and muscle were able to heal his bone simply couldn’t bear weight anymore. After his amputation surgery, however, the light came back into this senior boy’s eyes and is now a ball of energy and fun!
In some cases, our team knows immediately that amputation is the best choice. After being hit by a car and likely dragged, Paver’s wounds were severe enough that our veterinary medical specialists worked quickly to remove the damaged limb so that this young pup was able to rapidly get his zest back! Paver now moves through life as if romping on three legs is all he’s ever known!
Occasionally, pups come to us after amputation has occurred, like Miss Nora. We don’t know her full story, but we do know that at just two months old one of her front legs had been removed, causing the remaining front leg to develop abnormally. Our staff and volunteer teams work daily to ensure she receives the care she needs, including a custom made sling that supports the front part of her body when she walks.
While It may feel sad or be hard to see a dog have only three legs, amputations are often the only way we can help dogs return to the feeling of normalcy after experiencing a traumatic event. It’s an honor to be able to provide the support these pups so deeply need and to help them find a loving home.
Psst. We have several other tripods available for adoption, too! Bryce, Magnum, Champ and Destiny
[ad_2]
[ad_1]
LA CROSSE, WI—In a formidable display of her newly acquired knowledge, local School of the Art Institute of Chicago freshman Laura Sellers excitedly told her parents all about the color blue when she was back home for a visit Thursday. “So, blue is a color—it’s sort of like purple, but completely different,” said Sellers, explaining that while she’s still no expert, there are actually a lot of practical applications for blue. “I don’t want to get too into the weeds, because it’s a bit complex, but trust me, blue actually shows up quite often in day-to-day life if you have an eye trained enough to notice it. Plus, there’s a lot of different kinds of blue—sky blue, robin’s-egg blue… Stop me if this is getting too complicated.” At press time, Sellers was reportedly frustrated that everyone in her hometown was too provincial to understand blue.
[ad_2]
[ad_1]
ProShare Advisors LLC decreased its holdings in shares of HCA Healthcare, Inc. (NYSE:HCA – Get Rating) by 6.5% in the 4th quarter, according to its most recent Form 13F filing with the SEC. The firm owned 30,690 shares of the company’s stock after selling 2,143 shares during the period. ProShare Advisors LLC’s holdings in HCA Healthcare were worth $7,364,000 as of its most recent SEC filing.
Other large investors also recently added to or reduced their stakes in the company. Ellevest Inc. boosted its stake in HCA Healthcare by 13.4% during the third quarter. Ellevest Inc. now owns 1,043 shares of the company’s stock valued at $192,000 after buying an additional 123 shares during the period. Daymark Wealth Partners LLC purchased a new stake in HCA Healthcare during the fourth quarter valued at about $705,000. Handelsbanken Fonder AB raised its position in HCA Healthcare by 2.0% during the third quarter. Handelsbanken Fonder AB now owns 36,950 shares of the company’s stock valued at $6,791,000 after purchasing an additional 708 shares in the last quarter. Greenleaf Trust raised its position in HCA Healthcare by 11.5% during the third quarter. Greenleaf Trust now owns 5,344 shares of the company’s stock valued at $982,000 after purchasing an additional 551 shares in the last quarter. Finally, Keybank National Association OH purchased a new stake in HCA Healthcare during the fourth quarter valued at about $495,000. Institutional investors own 64.60% of the company’s stock.
Shares of HCA opened at $281.21 on Friday. The business’s 50 day moving average price is $258.39 and its 200-day moving average price is $242.29. HCA Healthcare, Inc. has a 52 week low of $164.47 and a 52 week high of $294.02. The stock has a market cap of $77.89 billion, a P/E ratio of 14.62, a P/E/G ratio of 1.94 and a beta of 1.64.
HCA Healthcare (NYSE:HCA – Get Rating) last issued its quarterly earnings results on Friday, January 27th. The company reported $4.64 EPS for the quarter, missing analysts’ consensus estimates of $4.79 by ($0.15). HCA Healthcare had a negative return on equity of 1,260.96% and a net margin of 9.37%. The company had revenue of $15.50 billion during the quarter, compared to the consensus estimate of $15.51 billion. On average, equities analysts anticipate that HCA Healthcare, Inc. will post 17.18 EPS for the current year.
The company also recently disclosed a quarterly dividend, which will be paid on Friday, June 30th. Investors of record on Friday, June 16th will be issued a $0.60 dividend. This represents a $2.40 dividend on an annualized basis and a yield of 0.85%. HCA Healthcare’s payout ratio is currently 12.48%.
HCA Healthcare announced that its Board of Directors has authorized a share repurchase plan on Friday, January 27th that authorizes the company to buyback $3.00 billion in shares. This buyback authorization authorizes the company to purchase up to 4.2% of its stock through open market purchases. Stock buyback plans are often an indication that the company’s management believes its shares are undervalued.
HCA has been the topic of a number of research reports. UBS Group raised their price target on HCA Healthcare from $237.00 to $296.00 and gave the company a “buy” rating in a research report on Friday, January 13th. JPMorgan Chase & Co. lifted their price objective on HCA Healthcare from $257.00 to $283.00 and gave the stock a “neutral” rating in a report on Wednesday. Mizuho lifted their price objective on HCA Healthcare from $279.00 to $298.00 and gave the stock a “buy” rating in a report on Tuesday, April 11th. Truist Financial lifted their price objective on HCA Healthcare from $270.00 to $290.00 and gave the stock a “buy” rating in a report on Monday, January 30th. Finally, Cantor Fitzgerald began coverage on HCA Healthcare in a report on Thursday. They issued an “overweight” rating and a $304.00 price objective on the stock. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating, seventeen have given a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, HCA Healthcare has a consensus rating of “Moderate Buy” and an average price target of $272.87.
In related news, CFO Bill B. Rutherford sold 30,000 shares of the business’s stock in a transaction that occurred on Friday, February 3rd. The shares were sold at an average price of $258.19, for a total value of $7,745,700.00. Following the completion of the transaction, the chief financial officer now directly owns 81,632 shares in the company, valued at approximately $21,076,566.08. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. In other HCA Healthcare news, SVP Christopher F. Wyatt sold 4,900 shares of the business’s stock in a transaction on Wednesday, February 1st. The shares were sold at an average price of $253.30, for a total transaction of $1,241,170.00. Following the completion of the sale, the senior vice president now directly owns 32,392 shares in the company, valued at approximately $8,204,893.60. The sale was disclosed in a document filed with the SEC, which is available through this link. Also, CFO Bill B. Rutherford sold 30,000 shares of the business’s stock in a transaction on Friday, February 3rd. The shares were sold at an average price of $258.19, for a total transaction of $7,745,700.00. Following the sale, the chief financial officer now owns 81,632 shares of the company’s stock, valued at $21,076,566.08. The disclosure for this sale can be found here. Insiders sold a total of 88,159 shares of company stock worth $22,688,959 in the last three months. Insiders own 1.60% of the company’s stock.
HCA Healthcare, Inc is a health care services company engaged in operating hospitals, freestanding surgery centers and emergency care facilities, urgent care facilities, walk-in clinics, diagnostic and imaging centers, radiation and oncology therapy centers, comprehensive rehabilitation and physical therapy centers, physician practices, home health, hospice, outpatient physical therapy home and community-based services providers, and various other facilities.
Receive News & Ratings for HCA Healthcare Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for HCA Healthcare and related companies with MarketBeat.com’s FREE daily email newsletter.
[ad_2]
ABMN Staff
Source link
[ad_1]
Put aside for a moment all that nutritional advice about eating fruits and vegetables, whole grains and lean proteins. Could one key to good health actually be a diet rich in … ice cream?
That’s the tantalizing question raised by a new story in the Atlantic, which states, “Studies show a mysterious health benefit to ice cream. Scientists don’t want to talk about it.”
The…
[ad_2]
[ad_1]
ABERDEEN, S.D. (Dakota News Now) – Medical marijuana patients in the Aberdeen area won’t have to travel hours to reach a dispensary from now on.
Just a year after medical marijuana dispensary permits were issued in Aberdeen, Dakota Herb became the first to open their doors with a soft opening on Tuesday, April 18th.
The business received one of Aberdeen’s six permits to open a dispensary, and their opening day has been highly anticipated.
”It’s great, the amount of phone calls we’ve got over the last six months asking when we’re going to open. It just forced our hand, we had to open here,” said Dakota Herb CEO Dalton Grimmius.
Grimmius said Aberdeen serves as a regional hub that can bring patients more access to medical marijuana. Dakota Herb has dispensaries open in Brandon, Huron, and Vermillion as well. Grimmius says he’s met patients from Aberdeen at other Dakota Herb locations.
“We’ve seen patients go to our Huron store and even to our Brandon store from Aberdeen before we opened here, so we knew there was a need for a medical dispensary in the area. I think we’re going to anticipate seeing people from Mobridge, Sisseton, Bowdle, pretty much everything in this northeast area,” said Grimmius.
As of April 17th, there were 8,977 approved patient cards for medical marijuana in the state.
As the first dispensary to open in the Hub City, Dakota Herb employees are hoping to serve as guides for community members hoping to utilize medical marijuana.
”We’re…
[ad_2]
MMP News Author
Source link
[ad_1]
Kestra Advisory Services LLC lowered its stake in shares of Amgen Inc. (NASDAQ:AMGN – Get Rating) by 14.8% during the fourth quarter, Holdings Channel reports. The institutional investor owned 55,910 shares of the medical research company’s stock after selling 9,718 shares during the period. Kestra Advisory Services LLC’s holdings in Amgen were worth $14,684,000 at the end of the most recent reporting period.
A number of other institutional investors have also recently added to or reduced their stakes in AMGN. EdgeRock Capital LLC acquired a new position in Amgen during the third quarter worth about $25,000. Leelyn Smith LLC raised its position in Amgen by 80.3% during the third quarter. Leelyn Smith LLC now owns 110 shares of the medical research company’s stock worth $25,000 after acquiring an additional 49 shares during the last quarter. Glassy Mountain Advisors Inc. acquired a new position in Amgen during the fourth quarter worth about $26,000. Legacy Bridge LLC raised its position in Amgen by 930.0% during the fourth quarter. Legacy Bridge LLC now owns 103 shares of the medical research company’s stock worth $27,000 after acquiring an additional 93 shares during the last quarter. Finally, RFP Financial Group LLC acquired a new position in Amgen during the fourth quarter worth about $33,000. Hedge funds and other institutional investors own 75.53% of the company’s stock.
AMGN opened at $250.00 on Friday. The company has a quick ratio of 1.10, a current ratio of 1.41 and a debt-to-equity ratio of 10.20. Amgen Inc. has a 52-week low of $223.30 and a 52-week high of $296.67. The company has a 50 day moving average of $239.01 and a two-hundred day moving average of $255.87. The company has a market cap of $133.56 billion, a P/E ratio of 20.64, a P/E/G ratio of 2.03 and a beta of 0.64.
Amgen (NASDAQ:AMGN – Get Rating) last released its quarterly earnings data on Tuesday, February 7th. The medical research company reported $4.09 earnings per share (EPS) for the quarter, topping the consensus estimate of $4.04 by $0.05. Amgen had a net margin of 24.89% and a return on equity of 359.47%. The company had revenue of $6.84 billion during the quarter, compared to the consensus estimate of $6.77 billion. During the same period in the previous year, the firm earned $4.36 earnings per share. Amgen’s revenue for the quarter was down .1% on a year-over-year basis. On average, analysts expect that Amgen Inc. will post 17.73 earnings per share for the current year.
The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, June 8th. Shareholders of record on Thursday, May 18th will be paid a dividend of $2.13 per share. The ex-dividend date of this dividend is Wednesday, May 17th. This represents a $8.52 annualized dividend and a yield of 3.41%. Amgen’s dividend payout ratio is currently 70.36%.
AMGN has been the subject of a number of research reports. SVB Securities cut their target price on shares of Amgen from $282.00 to $267.00 in a research report on Thursday, February 2nd. Truist Financial cut their price objective on shares of Amgen from $280.00 to $260.00 and set a “buy” rating for the company in a research report on Monday, February 13th. Argus cut their price objective on shares of Amgen from $300.00 to $270.00 in a research report on Monday, February 6th. Wells Fargo & Company raised shares of Amgen from an “equal weight” rating to an “overweight” rating and cut their price objective for the company from $275.00 to $265.00 in a research report on Monday, March 13th. Finally, Cowen cut their price objective on shares of Amgen from $307.00 to $289.00 and set an “outperform” rating for the company in a research report on Wednesday, February 1st. Four equities research analysts have rated the stock with a sell rating, three have given a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of “Hold” and an average price target of $251.25.
Amgen, Inc is a biotechnology company, which engages in the discovery, development, manufacture, and marketing of human therapeutics. It operates through Human Therapeutics segment. The company was founded by William K. Bowes, Jr., Franklin Pitcher Johnson, Jr., George B. Rathmann, and Joseph Rubinfeld on April 8, 1980 and is headquartered in Thousand Oaks, CA.
Want to see what other hedge funds are holding AMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen Inc. (NASDAQ:AMGN – Get Rating).
Receive News & Ratings for Amgen Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Amgen and related companies with MarketBeat.com’s FREE daily email newsletter.
[ad_2]
ABMN Staff
Source link
[ad_1]
Opinions expressed by Entrepreneur contributors are their own.
Medical tech (medtech) startups found themselves flush with cash a couple of years ago for quite obvious reasons. Pandemic-fuelled investment pushed VC funding for medtech and health-focused companies to unforeseen heights, ensuring that exemplary companies creating innovative technology to boost our collective health got the backing they deserved.
But times have certainly changed. The tech industry now finds itself reckoning with a banking crisis and VCs shifting priorities (and funds) towards scorching hot generative AI projects. That shift has caused funding for early-stage medtech companies to decline significantly, with numbers sliding by the billions across the board for digital health projects.
Related: Areas in Medtech That Need Innovative Entrepreneurs
To clarify, the funding well has not completely dried up for medtech projects. But the industry has become far more competitive now that the pandemic has moved to the periphery of public consciousness. But it’s unfair to place the entire blame for VCs pivoting away from medtech solely on the world emerging from COVID; there are other contributing factors driving entrepreneurs and liquidity providers to consider other industries.
For one, medtech is not a trend-proof industry immune to wider economic conditions. And although the digital health industry has seen a huge boom in the past decade, macro-level trends do eventually shift to something newer and more enthralling. AI has become a scene-stealer in terms of tech funding, and while many medtech companies champion AI use to help upgrade multiple aspects of healthcare, other projects might feel like there’s no outside funding to turn to.
Another factor that could contribute to the slowdown of VC funding in medtech is the pace at which health developments move, particularly in testing and regulation. While blockchain and AI projects can enjoy building in a regulatory gray area (for now), any medtech device or solution has to undergo strict review to become widely available to consumers. This is where we often see a collision when revenue-driven startup ideologies and rigorous healthcare standards meet, whether it’s the FDA or another regulatory body.
With this in mind, it makes sense as to why the VC mentality doesn’t always mesh well with an industry that relies heavily on regulatory clearance to progress. A growth-minded VC familiar with the nimble pace of a spritely tech startup is probably in for a rude awakening when a medtech company can’t grow at the speed it wants it to.
But there are a few ways for medtech companies to adapt in a funding drought, whether it’s exploring different funding sources or reevaluating their value proposition.
Related: 3 Alternatives to Venture Capital Funding for Startups
In a way, the medtech industry is much better equipped to survive a downturn in outside funding because it was one of the first modern tech sectors to learn about the importance of flushing out bad actors. It’s a harsh lesson that nascent industries such as crypto now face and generative AI projects will likely face in the future as the moral and societal problems of its development are called into question, even by its industry peers.
And when a scandal involving generative AI eventually does happen, outside funding will inevitably turn back towards industries that could withstand it the first few times.
It’s never a good indicator when companies in burgeoning tech sectors make cuts to their ethics teams; this is another leg up that medtech companies have over other industries. The ghost of Theranos still looms large over any public-facing medtech development, which is shockingly effective at keeping most projects ethically in line. Medtech founders understand that you can’t build products that affect people’s health with an MBA and a dream; it is a field that requires some sort of background and experience to execute effectively.
That being said, there are also spaces in medtech development for entrepreneurs to explore that don’t directly impact consumers’ health but assist the medical sector in other ways.
Entrepreneurs and developers in medtech should shift their focus on projects that either address the most common pain points in healthcare or projects that bridge different industries to create innovative healthcare solutions. It requires more creativity, but repurposing technological facets of other industries can help address very real challenges in healthcare.
For instance, in 2022 alone, more than 40 million Americans had their medical records exposed through data breaches according to an analysis from USA Today. These breaches only build on a recurring critique of the barriers for patients to have access to their medical records across health systems, either for their safekeeping or to understand their own medical history and needs.
To help solve these issues, smart-document SaaS provider ShelterZoom developed one of its key products for use in healthcare to empower patients to have full access and control of their medical records. The idea is to help patients outmaneuver the crushing bureaucracy many people face when seeing multiple doctors or specialists.
This clearly illustrates how development that utilizes tech infrastructure from a completely unrelated industry can bolster medtech’s positive impacts through specific, clever reinterpretation. And these kinds of developments can often clear regulatory hoops much faster than medtech that directly impacts medical practices and procedures.
It’s understandably difficult for medtech companies to get the same amount of attention that they used to. But it’s not impossible to stand out to outside investors, even when the trends aren’t necessarily in an industry’s favor. Likewise, it’s important to look outside of the VC bubble to help drive growth-stage development, and part of that requires creating a product that can stand on its own merits.
[ad_2]
Ariel Shapira
Source link
[ad_1]
Medical experts at Moderna say they are confident that groundbreaking new vaccines for cancer, cardiovascular and autoimmune diseases, and other conditions will be ready by 2030 due to cutting-edge research into developing personalized mRNA vaccines. What do you think?
“Imagine not wanting to die.”
Leo Guichard, Furniture Assembler
“I’m sure we can come up with new ways to kill people to pick up the slack.”
Laszlo Sullivan, Narcotics Importer
“I thought there were already vaccines that caused those diseases.”
Grace Lee, Hologram Tester
[ad_2]
[ad_1]
Bernardo Wealth Planning LLC trimmed its stake in Abbott Laboratories (NYSE:ABT – Get Rating) by 8.2% during the fourth quarter, Holdings Channel reports. The fund owned 2,400 shares of the healthcare product maker’s stock after selling 213 shares during the period. Bernardo Wealth Planning LLC’s holdings in Abbott Laboratories were worth $264,000 as of its most recent filing with the Securities & Exchange Commission.
Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. JDM Financial Group LLC purchased a new stake in shares of Abbott Laboratories during the 4th quarter valued at approximately $26,000. EdgeRock Capital LLC purchased a new stake in shares of Abbott Laboratories during the 3rd quarter valued at approximately $29,000. Johnson Midwest Financial LLC lifted its stake in shares of Abbott Laboratories by 28.7% during the 3rd quarter. Johnson Midwest Financial LLC now owns 560 shares of the healthcare product maker’s stock valued at $35,000 after buying an additional 125 shares in the last quarter. Arcus Capital Partners LLC purchased a new stake in shares of Abbott Laboratories during the 4th quarter valued at approximately $35,000. Finally, Glassy Mountain Advisors Inc. purchased a new stake in shares of Abbott Laboratories during the 4th quarter valued at approximately $44,000. 72.93% of the stock is currently owned by hedge funds and other institutional investors.
In other news, EVP Andrea F. Wainer sold 679 shares of the firm’s stock in a transaction dated Wednesday, March 1st. The shares were sold at an average price of $100.70, for a total value of $68,375.30. Following the completion of the sale, the executive vice president now directly owns 70,427 shares of the company’s stock, valued at approximately $7,091,998.90. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. In other news, SVP Randel William Woodgrift sold 1,032 shares of the firm’s stock in a transaction dated Wednesday, March 1st. The shares were sold at an average price of $100.70, for a total value of $103,922.40. Following the completion of the sale, the senior vice president now directly owns 52,203 shares of the company’s stock, valued at approximately $5,256,842.10. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, EVP Andrea F. Wainer sold 679 shares of the firm’s stock in a transaction dated Wednesday, March 1st. The stock was sold at an average price of $100.70, for a total transaction of $68,375.30. Following the completion of the sale, the executive vice president now directly owns 70,427 shares of the company’s stock, valued at $7,091,998.90. The disclosure for this sale can be found here. Insiders have sold a total of 1,971 shares of company stock valued at $199,140 in the last quarter. Insiders own 1.10% of the company’s stock.
A number of brokerages recently commented on ABT. Wells Fargo & Company dropped their price target on shares of Abbott Laboratories from $140.00 to $136.00 and set an “overweight” rating on the stock in a research note on Wednesday, April 5th. Sanford C. Bernstein increased their target price on shares of Abbott Laboratories from $125.00 to $132.00 and gave the stock an “outperform” rating in a research note on Thursday, January 26th. StockNews.com assumed coverage on shares of Abbott Laboratories in a research note on Thursday, March 16th. They issued a “buy” rating on the stock. SVB Leerink increased their target price on shares of Abbott Laboratories from $90.00 to $102.00 and gave the stock a “market perform” rating in a research note on Friday, March 31st. Finally, Barclays increased their target price on shares of Abbott Laboratories from $122.00 to $125.00 and gave the stock an “overweight” rating in a research note on Friday, January 27th. One research analyst has rated the stock with a sell rating, four have issued a hold rating and eleven have assigned a buy rating to the company. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $121.88.
ABT stock opened at $103.70 on Tuesday. The company has a debt-to-equity ratio of 0.39, a quick ratio of 1.23 and a current ratio of 1.63. Abbott Laboratories has a 52 week low of $93.25 and a 52 week high of $124.35. The firm’s fifty day moving average is $102.99 and its 200 day moving average is $104.43. The firm has a market cap of $180.23 billion, a P/E ratio of 26.52, a P/E/G ratio of 4.71 and a beta of 0.67.
Abbott Laboratories (NYSE:ABT – Get Rating) last released its earnings results on Wednesday, January 25th. The healthcare product maker reported $1.03 EPS for the quarter, beating the consensus estimate of $0.90 by $0.13. The company had revenue of $10.09 billion for the quarter, compared to analyst estimates of $9.69 billion. Abbott Laboratories had a net margin of 15.88% and a return on equity of 26.09%. The firm’s quarterly revenue was down 12.0% compared to the same quarter last year. During the same quarter last year, the firm earned $1.32 EPS. Research analysts predict that Abbott Laboratories will post 4.38 earnings per share for the current year.
The company also recently declared a quarterly dividend, which will be paid on Monday, May 15th. Shareholders of record on Friday, April 14th will be issued a $0.51 dividend. This represents a $2.04 dividend on an annualized basis and a yield of 1.97%. The ex-dividend date of this dividend is Thursday, April 13th. Abbott Laboratories’s dividend payout ratio (DPR) is presently 52.17%.
Abbott Laboratories engages in the discovery, development, manufacture, and sale of a broad and diversified line of health care products. It operates through the following business segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The Established Pharmaceutical Products segment refers to the international sales of a line of branded generic pharmaceutical products.
Want to see what other hedge funds are holding ABT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Abbott Laboratories (NYSE:ABT – Get Rating).
Receive News & Ratings for Abbott Laboratories Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Abbott Laboratories and related companies with MarketBeat.com’s FREE daily email newsletter.
[ad_2]
ABMN Staff
Source link
